This commentary summarizes the discussion of a multidisciplinary group of experts about drug shortages to highlight successes, opportunities for improvement, trends to consider, and strategies to plan for shortages. The group recommended actions needed to guide prevention and mitigation efforts such as developing best practices for use of high-alert drugs during shortages, increasing manufacturer transparency, and enhancing Food and Drug Administration improvement and communication activities.